Notum has recently been identified as a negative regulator of Wnt signaling through the removal of an essential palmitoleate group from Wnt proteins. There are emerging reports that Notum plays a role in human disease, with published data suggesting that targeting Notum could represent a new therapeutic approach for treating cancer, osteoporosis and neurodegenerative disorders. Complementary hit-finding strategies have been applied with successful approaches that include high-throughput screening, activity-based protein profiling, screening of fragment libraries and virtual screening campaigns. Structural studies are accelerating the discovery of new inhibitors of Notum. Three fit-for-purpose examples are LP-922056, ABC99 and ARUK3001185. The application of these small-molecule inhibitors is helping to further advance an understanding of the role Notum plays in human disease.
CITATION STYLE
Zhao, Y., Jolly, S., Benvegnu, S., Yvonne Jones, E., & Fish, P. V. (2021). Small-molecule inhibitors of carboxylesterase Notum. Future Medicinal Chemistry, 13(11), 1001–1015. https://doi.org/10.4155/fmc-2021-0036
Mendeley helps you to discover research relevant for your work.